Documents unsealed in Alaska show that Eli Lilly sales reps touting Zyprexa were told to "neutralize the diabetes/hyperglycemia issue" that arose when doctors started pointing out that the drug might lead to the disease. "The competition wins when we are distracted into talking about diabetes," the documents state. Lilly says it hasn't downplayed Zyprexa's risks and that the documents are "a tiny fraction" of those provided as part of the Alaska lawsuit over the drug. Report